

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**3DMed**

**思路迪**

**3D Medicines Inc.**

**思路迪医药股份有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1244)**

## **CHANGE OF NON-EXECUTIVE DIRECTOR AND CHANGE OF COMPOSITION OF THE AUDIT COMMITTEE**

The board of directors (the “**Board**”) of 3D Medicines Inc. (the “**Company**” together with its subsidiaries, the “**Group**”) announces the following changes of directors (“**Director(s)**”) of the Company:

### **RETIREMENT OF NON-EXECUTIVE DIRECTOR**

Mr. Zhu Pai (“**Mr. Zhu**”) will retire as non-executive Director upon the expiry of his term of office after conclusion of the annual general meeting of the Company to be held on June 30, 2025 as he wishes to devote more time to pursue his other work engagements. Mr. Zhu confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company (the “**Shareholder(s)**”) and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to express its sincere gratitude to Mr. Zhu for his valuable contributions during his tenure of office as a non-executive Director.

### **PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR**

The Board is delighted to announce that following Mr. Zhu’s retirement, the Board proposes to appoint Mr. Zhu Jinqiao (朱晉橋) as a non-executive Director with effect from June 30, 2025, the date of the approval at the general meeting of the Company.

Mr. Zhu Jinqiao, aged 59, has over 27 years of experience in investment and entrepreneurship consulting. From November 1996 to May 2008, he served as the chairman of the board and general manager of Shenzhen Langfeng Industry Development Co., Ltd.\* (深圳市朗峰投資發展有限公司), a company principally engaged in business investment, where he was primarily responsible for making major decisions such as development plan and investment plan. From August 2007 to August 2020, Mr. Zhu Jinqiao served as the chairman of the board and general manager of Shenzhen Efung Venture Capital Co., Ltd.\* (深圳市倚鋒創業投資有限公司), a company principally engaged in venture capital investment and entrepreneurship consulting, where he was primarily responsible for making major decisions such as development plan and investment plan. Since March 2012, he has been serving as the controller of Shenzhen Efung Investment Management Enterprise (Limited Partnership)\* (深圳市倚鋒投資管理企業(有限合伙)) (“**Shenzhen Efung Investment**”), where he is primarily responsible for leading and managing the company team, making decisions on major issues and managing partnership affairs of the funds.

Since April 2022, he has been serving as a director (re-designated as a non-executive director on August 2022) of Genuine Biotech Limited (真實生物科技有限公司), a company principally engaged in biotech, where he is primarily responsible for providing guidance and overseeing its management and operations. Mr. Zhu Jinqiao is the father of Mr. Zhu Pai, who is retiring from the position as a non-executive Director.

Mr. Zhu Jinqiao graduated from School of Information Communication of Chinese People's Liberation Army National University of Defense Technology\* (中國人民解放軍國防科技大學信息通信學院) (formerly known as Chinese People's Liberation Army Communication Command College\* (中國人民解放軍通信指揮學院)) in the PRC in June 2010 in communication and information system management. Mr. Zhu Jinqiao also obtained an executive master of business administration degree from Zhongnan University of Economics and Law (中南財經政法大學) in the PRC in June 2011 and an executive master of business administration degree from Cheung Kong Graduate School of Business (長江商學院) in the PRC in September 2015. Mr. Zhu Jinqiao obtained the China Securities Investment Fund Industry Practice Certificate (中國證券投資基金業從業證書) from the Asset Management Association of China (中國證券投資基金業協會) in the PRC in May 2018.

Mr. Zhu Jinqiao has obtained a number of awards, including the “2019-2020 Top 10 Investors in China's Healthcare Industry (2019-2020 年度中國醫療健康產業十佳投資人物)” granted by Chinese Venture (融資中國) in August 2020, one of the “2020 Best Investors in Healthcare Industry (2020年度醫療健康行業最佳投資人)” granted by Securities Times (證券時報) in August 2020, “2020 China Shenzhen Venture Capital Leaders (2020 年度中國深圳創投領袖人物)” granted by Shenzhen Investment Chamber of Commerce\* (深圳市投資商會) in March 2021, “2020 Best Investors in the General Health Field (2020 年度大健康領域最佳投資人)” granted by Investors.cn (投資家網) in April 2021, “2020-2021 Top 20 Chinese Healthcare Investors (2020-2021 年度中國醫療健康投資人物 TOP 20)” granted by Chinese Venture (融資中國) in July 2021, “2021 Best Investors in Healthcare Industry (2021 年度醫療健康行業最佳投資人)” granted by Securities Times in August 2021, “2020 Top 100 Best Venture Capital Investors in China (2020 年度中國最佳創業投資人 TOP 100)” granted by CVINFO (投中信息) in September 2021, the “2022 Top 50 Most Influential Investors” (2022 年度最具影響力投資人 TOP 50) granted by China Healthcare Consulting (CHC 醫療諮詢) and Citic Securities (中信証券) in April 2023 and the “2023 Top 30 Most Influential Investors in China” (2023 年中國最具影響力的 30 位投資人) granted by FORTUNE (《財富》) and Zero2IPO Research (清科研究中心) in November 2023.

Mr. Zhu Jinqiao was a director or executive partner of the following companies and partnership which were dissolved during the period when he was one of their directors or executive partner:

<b>Name of company or partnership</b>	<b>Place of establishment</b>	<b>Nature of business</b>	<b>Details of the proceeding involved</b>
Xinyu Yijin Investment Management Center (Limited Partnership) * 新余易金投資管理中心 (有限合夥)	PRC	Business investment	Dissolved on January 17, 2018
Shenzhen Tongyong Lianke Investment Co., Ltd.* (深圳市通用聯科投資有限公司)	PRC	Business investment	Dissolved on January 6, 2009

<b>Name of company or partnership</b>	<b>Place of establishment</b>	<b>Nature of business</b>	<b>Details of the proceeding involved</b>
Suzhou Keshan MicroElectronics Co., Ltd.* (蘇州科山微電子科技 有限公司)	PRC	Design, R&D and sales of semiconductor integrated circuit	Dissolved on October 24, 2017
Guangzhou Liansuo Network Technology Co., Ltd.* (廣州市聯索網絡科技 有限公司)	PRC	R&D and technical services of computer network technology, wholesale and retail trade and internet information service	Dissolved on June 19, 2014
Shenzhen Langfeng Investment Development Co., Ltd.* (深圳市朗峰投資發展 有限公司)	PRC	Business investment and domestic trade	Dissolved on September 14, 2011
Shenzhen Langfeng Investment Development Co., Ltd.* (深圳市朗峰投資發展 有限公司)	PRC	Property management	Dissolved on March 31, 2011

The term of Mr. Zhu Jinqiao's services as a non-executive Director is for three years commencing today and is subject to retirement and re-election at the annual general meetings of the Company pursuant to the Articles of Association of the Company. Mr. Zhu Jinqiao will not receive any remuneration in connection with his role as a non-executive director of the Company under the terms of this agreement.

Mr. Zhu Jinqiao is the controller of Shenzhen Efung Investment. Shenzhen Efung Investment is, in turn, controls (for the purpose of Part XV of the Securities and Futures Ordinance) Shanghai Zhenlu Enterprise Management Consulting Partnership (Limited Partnership).

As of the date of this announcement, to the best knowledge of the Directors, Shanghai Zhenlu Enterprise Management Consulting Partnership (Limited Partnership) holds 5.31% of the ordinary shares of the Company (the "Shares"). Accordingly, Mr. Zhu Jinqiao is deemed to be interested in 5.31% of the Shares.

As at the date of this announcement and save as disclosed above, Mr. Zhu Jinqiao confirms that he did not have any relationship with any director, senior management, chief executive or substantial shareholder or controlling shareholder of the Company and hold no other position within the Group. Within the meaning of Part XV of the Securities and Futures Ordinance, Mr. Zhu Jinqiao also confirms that he does not have any interest in the shares or underlying shares of the Company and he has not held any directorship in other listed public companies in Hong Kong or overseas in the last three years and he does not have any major appointments and professional qualifications. There is no other matter that needs to be brought to the attention of the Shareholders and there is no other information which is required to be disclosed pursuant to any of the requirements of rule 13.51(2) of the Rules Governing the Listing of Securities on the Stock Exchange.

## **CHANGE OF COMPOSITION OF THE AUDIT COMMITTEE**

The Board hereby announces that Mr. Zhou Feng, a non-executive director, has been appointed as a member of the audit committee of the Company (“**Audit Committee**”), with effect from June 30, 2025.

By Order of the Board  
**3D Medicines Inc.**  
**Dr. Gong Zhaolong**  
*Chairman of the Board and Executive Director*

Hong Kong, June 5, 2025

*As at the date of this announcement, the Board of Directors of the Company comprises Dr. GONG Zhaolong as executive Director, Mr. ZHU Pai, Mr. ZHOU Feng and Ms. CHEN Yawen as non-executive Directors, and Dr. LI Jin, Dr. LIN Tat Pang and Mr. LIU Xinguang as independent non-executive Directors.*